Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + quadrivalent HPV vaccine
- Development stage
- Unknown
- Lead developer
- Buhai Wang
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
This combination therapy consists of the PD-1 inhibitor sintilimab and the quadrivalent human papillomavirus (HPV) vaccine (Gardasil). It is being investigated as a novel therapeutic approach for patients with recurrent or metastatic cervical cancer who have failed or are intolerant to standard first-line treatments. Sintilimab is a monoclonal antibody that blocks the PD-1 receptor, thereby restoring T-cell mediated anti-tumor immunity. Gardasil is a recombinant vaccine containing virus-like particles (VLPs) of the L1 capsid protein from HPV types 6, 11, 16, and 18. In this therapeutic setting, the vaccine is intended to stimulate an HPV-specific immune response that is further amplified by the checkpoint inhibition provided by sintilimab. A Phase II clinical trial led by Buhai Wang demonstrated promising results, including a 53.8% objective response rate and a 76.9% disease control rate in patients with advanced cervical cancer.
- Brand names
- Tyvyt + Gardasil
- Other names
- sintilimab + Gardasilquadrivalent HPV vaccine + sintilimabPD-1 monoclonal antibody + quadrivalent HPV vaccine
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + quadrivalent HPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + quadrivalent HPV vaccine.